Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Provides free water and sodium chloride to expand extracellular fluid volume and correct electrolyte imbalances. Dextrose is metabolized to carbon dioxide and water, providing calories and preventing ketosis. Sodium chloride dissociates into sodium and chloride ions, maintaining osmotic pressure and acid-base balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
FDA-approved for fluid and electrolyte replacement,Treatment of dehydration,Maintenance of fluid and electrolyte balance,Used as a vehicle for intravenous drug administration (off-label),Correction of hyponatremia (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult: 500-1000 m L at 50-100 m L/hour, adjusted based on clinical status.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Dextrose: not applicable (endogenous substrate); glucose half-life ~1.5–2 hours in circulation under normal conditions, prolonged in hyperglycemia. Sodium chloride: not applicable as ions are electrolytes with no elimination half-life; renal clearance depends on glomerular filtration and tubular reabsorption.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose undergoes glycolysis and subsequent metabolism via the tricarboxylic acid cycle. Sodium and chloride are primarily excreted unchanged by the kidneys.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Dextrose is fully metabolized to carbon dioxide and water; no significant renal excretion of intact dextrose. Sodium chloride is excreted renally; sodium and chloride ions are eliminated via kidneys, with excretion proportional to intake and renal function. No biliary or fecal elimination of intact components.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: not bound to plasma proteins. Sodium chloride: sodium and chloride ions are not protein-bound (<1% bound).
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: ~0.2 L/kg (distributes in extracellular fluid). Sodium: ~0.2–0.3 L/kg (mainly extracellular). Chloride: ~0.2–0.3 L/kg. Clinical meaning: Vd approximates extracellular fluid volume; expansion of Vd indicates fluid overload.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% for both dextrose and sodium chloride. Not administered by other routes.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific renal dose adjustment; use caution in renal impairment due to sodium load. Monitor fluid status. GFR <30 m L/min: consider reduced rate or use of alternative fluids.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific hepatic adjustment required. Use standard dosing; monitor for fluid overload in severe hepatic impairment (Child-Pugh C).
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Weight-based: 5-10 m L/kg/dose as maintenance fluid, administered at 100-150 m L/kg/day for infants and 60-80 m L/kg/day for older children, adjusted per clinical need.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Start at lower end of infusion rate (50 m L/hour) and titrate based on renal function and cardiac status. Monitor for hyperglycemia and fluid overload due to reduced renal function and comorbidities.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of fluid overload, especially in patients with heart failure, renal impairment, or edema,Hyperglycemia in diabetic patients or those with glucose intolerance,Hypersensitivity reactions (rare),Electrolyte disturbances (e.g., hypernatremia, hyponatremia, hyperchloremia) with improper use,Not for use in patients with increased intracranial pressure or severe renal impairment without careful monitoring
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperglycemia with severe dehydration,Intracranial or intraspinal hemorrhage (when used as a vehicle),Severe electrolyte disturbances without correction,Allergy to dextrose or sodium chloride
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions, but patients should avoid high-sodium foods to prevent hypernatremia.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Dextrose 5% and sodium chloride 0.9% are not teratogenic. No known fetal risks at recommended doses. First trimester: No evidence of harm. Second trimester: No risk. Third trimester: No risk.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Compatible with breastfeeding. Dextrose and sodium chloride are normal constituents of breast milk. M/P ratio not applicable as they are endogenous substances. No adverse effects expected.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No dose adjustment required. Pregnancy does not significantly alter the pharmacokinetics of dextrose or sodium chloride. Dosing is based on clinical need for fluid and electrolyte replacement.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
This solution is isotonic (308 m Osm/L) and provides 170 kcal/L from dextrose. It is contraindicated in patients with hyperglycemia, hypernatremia, or fluid overload. Use with caution in renal impairment, heart failure, or elderly patients. Monitor serum glucose, sodium, and volume status. Do not administer if solution is discolored or contains particulates.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Inform your healthcare provider if you have diabetes, high blood pressure, or heart failure.,Tell your doctor if you experience headache, swelling, shortness of breath, or dry mouth.,This medication provides sugar and salt; avoid additional sodium in your diet unless directed.,Report any pain, redness, or swelling at the IV site.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Provides free water and sodium chloride to expand extracellular fluid volume and correct electrolyte imbalances. Dextrose is metabolized to carbon dioxide and water, providing calories and preventing ketosis. Sodium chloride dissociates into sodium and chloride ions, maintaining osmotic pressure and acid-base balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult: 500-1000 m L at 50-100 m L/hour, adjusted based on clinical status.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% and sodium chloride 0.9% are not teratogenic. No known fetal risks at recommended doses. First trimester: No evidence of harm. Second trimester: No risk. Third trimeste. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.